The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2).
 
Pooja Ghatalia
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)
 
Eric Ross
Stock and Other Ownership Interests - Procter & Gamble
 
Matthew Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - Adicet Bio; AVEO; Exelixis; Merck
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - DAVA Oncology
 
Fern Anari
No Relationships to Disclose
 
Philip Abbosh
Stock and Other Ownership Interests - Abyost PHarmaceuticals
Consulting or Advisory Role - ArTara Therapeutics
Research Funding - Adaptive Biotechnologies; Janssen Oncology (Inst); natera
Patents, Royalties, Other Intellectual Property - Intravesical imidazolium compunds; novel kidney cancer vaccine (Inst); urine biomarkers patent application
 
William Tester
No Relationships to Disclose
 
Tracy Rose
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GeneCentric (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Suzanne Cole
Research Funding - Exelixis (Inst); Merck (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Clovis Oncology; Dendreon; Foundation Medicine; Gilead Sciences; Janssen Scientific Affairs; Myovant Sciences; Procept Biorobotics; Progenics; Seagen
 
James Mark
No Relationships to Disclose
 
Rosalia Viterbo
No Relationships to Disclose
 
Erika Jerome
No Relationships to Disclose
 
Eric Horwitz
No Relationships to Disclose
 
Mark Hallman
Consulting or Advisory Role - Evolent
Travel, Accommodations, Expenses - Evolent
(OPTIONAL) Uncompensated Relationships - Varian Medical Systems
 
Andres Correa
No Relationships to Disclose
 
Marc Smaldone
No Relationships to Disclose
 
Robert Uzzo
Consulting or Advisory Role - Merck; Merck; Pfizer
 
David Chen
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
 
Alexander Kutikov
Travel, Accommodations, Expenses - Pfizer
 
Elizabeth Plimack
Consulting or Advisory Role - 23andMe; Abbvie; Adaptimmune; Astellas Pharma; AstraZeneca; Aura Biosciences; Bristol-Myers Squibb/Medarex; Eisai; EMD Serono; Merck; Pfizer; Seagen; Signatera; Synthekine
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Daniel Geynisman
Honoraria - Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Pfizer; Seattle Genetics/Astellas
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); CG Oncology (Inst); Harpoon therapeutics (Inst); Merck (Inst)